The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes

A somatic mutation in the JH2 autoinhibitory domain of the Janus kinase 2 (JAK2) tyrosine kinase was recently described in polycythemia vera, essential thrombocythemia, and myelofibrosis with myeloid metaplasia. The prevalence of this mutation in either “atypical” myeloproliferative disorders (MPDs)...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Steensma, David P., Dewald, Gordon W., Lasho, Terra L., Powell, Heather L., McClure, Rebecca F., Levine, Ross L., Gilliland, D. Gary, Tefferi, Ayalew
Médium: Artigo
Jazyk:Inglês
Vydáno: The American Society of Hematology 2005
Témata:
Clinical Observations, Interventions, and Therapeutic Trials
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895198/
https://ncbi.nlm.nih.gov/pubmed/15860661
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2005-03-1183
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky